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We have used the budding yeast Saccharomyces cerevisiae to identify genes that may confer sensitivity in vivo
to the antimalarial and cytotoxic agent cryptolepine. Five S. cerevisiae strains, with different genetic back-
grounds in cell permeability and DNA damage repair mechanisms, were exposed to several concentrations of
cryptolepine. Cryptolepine showed a relatively mild toxicity for wild-type strains, which was augmented by
either increasing cell permeability (erg6 or ISE2 strains) or disrupting DNA damage repair (rad52 strains).
These results are compatible with the ability of cryptolepine to intercalate into DNA and thus promote DNA
lesions. The effects of low concentrations of cryptolepine (20% and 40% inhibitory concentrations [IC20 and
IC40]) were analyzed by comparing the gene expression profiles of treated and untreated erg6 yeast cells.
Significant changes in expression levels were observed for 349 genes (117 upregulated and 232 downregulated).
General stress-related genes constituted the only recognizable functional cluster whose expression was in-
creased upon cryptolepine treatment, making up about 20% of upregulated genes. In contrast, analysis of the
characteristics of downregulated genes revealed a specific effect of cryptolepine on genes related to iron
transport or acid phosphatases, as well as a significant proportion of genes related to cell wall components. The
effects of cryptolepine on the transcription of iron transport-related genes were consistent with a loss of
function of the iron sensor Aft1p, indicating a possible disruption of iron metabolism in S. cerevisiae. Since the
interference of cryptolepine with iron metabolism is considered one of its putative antimalarial targets, this
finding supports the utility of S. cerevisiae in drug-developing schemes.
Cryptolepine is the main indoloquinoline alkaloid found in
the roots of the climbing shrub Cryptolepis sanguinolenta
(Periplocaceae). In West Africa, decoctions of the roots of C.
sanguinolenta are used in traditional medicine to treat malaria
as well as a variety of other infectious diseases (27). Cryptol-
epine (Fig. 1) has shown in vitro antiplasmodial activity (27),
but this alkaloid also has cytotoxic properties in several cell
lines, and the mechanisms involved may include intercalation
into DNA, as well as inhibition of topoisomerase II and DNA
synthesis (4). The mode of cryptolepine intercalation into
DNA is peculiar in that it occurs at nonalternating C/G se-
quences (12).
Regardless of the binding of cryptolepine to DNA (3, 12),
investigations into its molecular mechanisms of action have
revealed that the antiplasmodial mode of action may be dif-
ferent from the cytotoxic mode of action. Cryptolepine shares
with chloroquine, and related quinoline antimalarial drugs, the
property of binding to heme and prevents its conversion to
hemazoin (28). The drug-heme complex is considered to be
toxic to the parasite.
Deeper knowledge of the different targets of cryptolepine
should help to elucidate the basis for the relative selectivity of
this alkaloid against malaria parasites and should assist in the
rational development of cryptolepine derivatives with en-
hanced antimalarial activities. The antimalarial activity of cryp-
tolepine is considered to be pleiotropic rather than dependent
on a unique mechanism. It may encompass many different
pathways, including binding to DNA, transcriptional inhibition
of certain genes, formation of drug-heme complexes, and its
accumulation in the parasite food vacuole (where hemoglobin
digestion takes place) and in other organelles (25, 27). Valu-
able insights into determinants of virulence, drug responses,
and cellular development in population structures of human
malaria parasites can be facilitated by the ongoing sequencing
of the P. falciparum genome (9) (available at the Plasmodium
falciparum Genome Database [http://www.tigr.org/tdb/edb2
/pfa1/htmls/]). A detailed understanding of the molecular bases
of drug response can be further facilitated by using simpler
model organisms, such as the budding yeast Saccharomyces
cerevisiae, the genome of which is fully annotated and widely
characterized (available at the Saccharomyces Genome Data-
base [SGD] [http://www.yeastgenome.org/]). This eukaryotic
model organism has proven to be a powerful genetic system for
testing drugs that can interact with DNA and/or modify gene
regulation, since it shares many common regulatory mecha-
nisms with vertebrates, ranging from cell cycle to transcrip-
tional regulation (14–16, 30).
To gain new insights into the role played by changes in the
transcriptome during exposure to cryptolepine, we have under-
taken a genomewide analysis using S. cerevisiae to identify
genes responsive to this drug. The main drawback of the use of
yeast in pharmacological studies is its resistance to many drugs
(15, 16), which is due to the strict permeability barrier formed
by the yeast cellular membrane. In a previous paper, we have
shown that yeast strains deficient in ergosterol synthesis (erg6
strains) are particularly sensitive to the antitumor antibiotic
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daunorubicin (14). In the erg6 background, we also demon-
strated the specific inhibition of genes involved in galactose
utilization by daunorubicin, and we suggested that this was
related to the presence of CpG steps in the recognition se-
quence of the main regulator for these genes, Gal4p (14). Here
we extend these studies to the antimalarial drug cryptolepine
by using the whole budding yeast transcriptome. We observed
specific changes in the transcriptome, rather than a general
malfunction of the transcriptional network. These results are
consistent with those observed in the transcription profiles
produced by other DNA-binding drugs in different cell types,
including S. cerevisiae (2, 10, 13, 21), and provide us with some
clues on the peculiar characteristics of cryptolepine effects in
vivo. From the analysis of transcriptional profiles, we found that
cryptolepine induced specific inhibition of several genes, mainly
genes involved in stress response and iron usage. Many of the
affected genes were controlled by Aft1p, the major iron-depen-
dent transcription factor in S cerevisiae (22). The similarities be-
tween transcriptome changes induced by cryptolepine and those
resulting from Aft1p loss of function suggest a mechanism of
disruption of iron uptake and/or signaling for at least part of the
cytotoxicity of cryptolepine. This effect may be central to under-
standing of the mechanisms underlying cryptolepine sensitivity in
both S. cerevisiae and Plasmodium spp.
MATERIALS AND METHODS
Cryptolepine preparation. Cryptolepine was isolated and purified as the hy-
drochloride salt from C. sanguinolenta as described elsewhere (29). It was freshly
prepared as a 1 mM stock solution in methanol and diluted to final concentra-
tions before use.
Yeast strains and growth assays. The following strains of Saccharomyces
cerevisiae were used: BY4741 (MATa his31 leu20 met150 ura30) and its
derived single deletion mutant strains BY4741erg6 (erg6::KanMX4) and
BY4741rad52 (rad52::KanMX4), available through EUROSCARF (Frankfurt,
Germany). Permeable yeast strains JN362a (MATa ura3-52 leu2 trp1 his7 ade1
ISE2) and JN394 (JN362a rad52::LEU2) (15) were obtained from J. Roca
(IBMB-CSIC, Barcelona, Spain).
The different yeast strains were precultured in complete YPD medium (10
g/liter yeast extract, 20 g/liter peptone, and 20 g/liter dextrose) at 30°C for 15 h
with shaking at 250 rpm in the dark. Before the strains were used for the different
experiments, the number of cells was standardized (optical density at 600 nm
[OD600], 0.05) using the same medium. Yeast was grown in triplicate in 96-well
microtiter plates in the same medium in the presence of different concentrations
of cryptolepine. Yeast growth was measured as OD600 units.
RNA preparation. Cultures were centrifuged for 5 min at 3,000 rpm, washed
with 5 ml MilliQ water, and subsequently centrifuged (the whole procedure was
repeated twice). Total RNA was extracted with the RiboPure yeast kit (Ambion,
Austin, TX) and quantified by spectrophotometry using a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE), and its integrity
was checked on agarose gels. The resulting total RNA was then treated with
DNase I (F. Hoffmann-La Roche, Basel, Switzerland) to remove any genomic
DNA.
DNA microarray analysis. Yeast genomic microchips were constructed in the
Institute of Biology and Biotechnology, Autonomous University of Barcelona,
Barcelona, Spain, by arraying 6,014 different PCR-amplified open reading frames
(ORFs) from S. cerevisiae (26). Fifteen micrograms of total RNA, isolated as
described above, was used for cDNA synthesis and labeling with Cy3-dUTP and
Cy5-dUTP fluorescent nucleotides by following an indirect labeling protocol
(CyScribe postlabeling kit; GE-Healthcare, New York, NY). Labeling efficiency
was evaluated by spectrophotometric measurement of Cy3 or Cy5 absorbance.
Microarray prehybridization was performed in 5 SSC (1 SSC is 0.15 M NaCl
plus 0.015 M sodium citrate [pH 7.0])–0.1% sodium dodecyl sulfate–1% bovine
serum albumin at 42°C for 45 min. Labeled cDNA was dried in a vacuum trap
and used as a probe after resuspension in 110 l of hybridization solution (50%
formamide, 5 SSC, 0.1% sodium dodecyl sulfate, 100 g/ml salmon sperm
DNA). Hybridization and washing were performed in a Lucidea Slide Pro system
(GE Healthcare, Uppsala, Sweden). Arrays were scanned with a GenePix 4000B
fluorescence scanner and analyzed by Genepix 5.0 Pro software (Axon Instru-
ments, MDS Analytical Technologies, Toronto, Ontario, Canada). Only spots
whose intensity was 1.5 times that of the background signal were selected for
further calculations. Eight sets of microarray data are presented here, corre-
sponding to treatments with two different cryptolepine concentrations (7.5 and
17 M, equivalent to 20% and 40% inhibitory concentrations [IC20 and IC40],
respectively), each performed in duplicate. Each RNA preparation was labeled
and hybridized twice, and dyes were swapped between treated and untreated
samples. Data are presented as fluorescence ratios of treated versus untreated
cell cultures.
qRT-PCR assay. An aliquot of RNA preparations from untreated and treated
samples, used in the microarray experiments, was used for quantitative real-time
reverse transcriptase PCR (qRT-PCR) follow-up studies. Two additional biolog-
ical replicates were performed as described above. First-strand cDNAs were
synthesized from 2 g of total, DNase I-treated RNA in a 20-l reaction volume
using the Omniscript RT kit (Qiagen, Valencia, CA) according to the manufac-
turer’s instructions. qRT-PCRs were performed in triplicate using the ABI Prism
7000 sequence detection system (Applied Biosystems, Foster City, CA) with the
Sybr green PCR master mix (Applied Biosystems). Gene-specific primers were
designed using Primer Express software (Applied Biosystems); primer sequences
are listed in Table 1. Amplified fragments were confirmed by sequencing in an
Applied Biosystems 3730 DNA analyzer, and the sequences were compared with
the genomic data published at the SGD. PCR conditions included an initial
denaturation step at 95°C for 10 min, followed by 40 cycles of a denaturation step
at 95°C for 15 s and an annealing/extension step at 60°C for 1 min. A final
dissociation curve was generated to verify that a single product was amplified. A
series of 10-fold dilutions of genomic DNA covering a total dilution range from
1 to 106 was used to generate the standard curves. Genomic DNA was purified
using a MasterPure yeast DNA purification kit (Epicentre) according to the
manufacturer’s protocol. Reactions in the absence of template and in the ab-
sence of enzyme were also performed in triplicate for each primer pair as
negative controls. The relative expression values of different genes were calcu-
lated from the threshold cycle (CT) by the CT method (17).
Data analysis. Dual logarithmic values of the ratios of fluorescence rates for
cryptolepine-treated versus untreated cells were used for subsequent analysis.
Because no significant differences were found between cells treated with 7.5
versus 17 M concentrations of cryptolepine (see below), the eight sets of
microarray data were considered equivalent and used accordingly. Differences in
fluorescence rates between treated and untreated cells for each ORF were
considered significant when the probability of the corresponding ratios being
equal to 1 was below 0.01 (two-tailed Student t test with logarithm-transformed
data from the eight hybridizations). Genes were classified by gene ontology (GO)
in the biological-process category (5) at the SGD page (http://www.yeastgenome
.org/).
Microarray data accession number. The entire set of microarray data has been
deposited in the GEO (Gene Expression Omnibus) database (http://www.ncbi
.nlm.nih.gov/projects/geo/) under accession number GSE12192.
RESULTS
Sensitivity of S. cerevisiae to cryptolepine. Figure 2 shows the
results of assays of yeast cell growth in the presence of different
concentrations of cryptolepine. The data presented correspond
to experiments consisting of continuous treatments of the dif-
ferent yeast strains for 4 h. Cell growth was determined as
described in Materials and Methods, and the IC40s calculated
from the plots can be seen in Fig. 2. We selected this rather
mildly inhibitory condition to ensure that the effects of the
drug on the yeast transcriptome were not a direct consequence
FIG. 1. Chemical structure of cryptolepine hydrochloride.
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of a general cytotoxic effect but more-direct, and somewhat
specific, effects on transcriptional levels; thus, this concentra-
tion was used in experiments aimed at isolating RNAs after
longer incubation times.
The most sensitive yeast strain was JN394 (ISE2 rad52)
(IC50, 20.29  1.77 M), followed by BY4741erg6 (IC50,
25.03  4.87 M). These results would indicate that damage/
repair mechanisms, together with cell permeability, are in-
volved in the toxicity of cryptolepine. To reduce the growth of
strain JN362a by 50% required a concentration almost twice
that required for the BY4741erg6 strain, whereas the JN394
ISE2 strain was twofold more sensitive than the isogenic strain
JN362a (Fig. 2). Since RAD52 function is central for DNA
repair by homologous recombination, this result suggests that
cryptolepine affects DNA repair mechanisms, in keeping with
the ability of cryptolepine to intercalate into DNA and trigger
genetic damage (1).
At cryptolepine concentrations below 10 M, higher sensi-
tivity was observed for the BY4741erg6 strain, despite its
RAD52 wild-type background (Fig. 2). Because we intended to
TABLE 1. Sequences of primers used for qRT-PCR assays
Gene and
primer Primer sequence Gene function
ACT1 Actin
for 5-TGTGTAAAGCCGGTTTTGCC-3
rev 5-TTGACCCATACCGACCATGAT-3
ARN2 ARN transporter family; recognizes
siderophore-iron chelatesfor 5-CGTGGAATGGAAAGAATTACAGG-3
rev 5-CCGTGCGTTTGATAGTACGATTT-3
FIT3 Mannoprotein, involved in the retention
of siderophore iron in the cell wallfor 5-TGTCTGGACTGGTGAAGGCAG-3
rev 5-GAAGTACTACTTGGAGACCAGGTGTTG-3
TIS11 mRNA-binding protein, involved in iron
homeostasisfor 5-TCGGCAGTTTCATTCTCTCCA-3
rev 5-CCCCGGTTGAATAGCGTTT-3
TPS1 Synthase subunit of trehalose-6-phosphate
synthase/phosphatase complexfor 5-CGACGAGAATGCGTGGTTG-3
rev 5-TTGGTGAACGTCTGGTTTGC-3
PHO5 Repressible acid phosphatase
for 5-CATGCTCGTGACTTCTTGGC-3
rev 5-GGTTTGGTTTTCGACCATGTAAC-3
HSP26 Small heat shock protein (sHSP) with
chaperone activityfor 5-AGAGGCTACGCACCAAGACG-3
rev 5-AGAATCCTTTGCGGGTGTGT-3
FIG. 2. Effects of cryptolepine on the cell growth of different Saccharomyces cerevisiae strains deficient in specific genes or combinations of
genes. (A) Effects of cryptolepine on the wild-type strain BY4741 and its derived mutant strains BY4741erg6 and BY4741rad52. (B) Effects on
the ISE2 strain JN362a and its rad52 derivative JN394. Each data point represents the percentage of relative growth (drug-treated compared to
control cells) versus the concentration of cryptolepine in the growth medium. Data are means  standard deviations from three independent
experiments.
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identify toxic effects independent of DNA damage, we used
this strain to analyze the effects of moderately cytotoxic
concentrations (IC20 and IC40) of cryptolepine in the transcrip-
tome of S. cerevisiae.
Effects of cryptolepine on the yeast transcriptome. Expres-
sion data from yeast cells treated with 7.5 or 17 M cryptol-
epine (the IC20 and IC40, respectively) and untreated cells
were compared after 15-h treatments. No significant differ-
ences were found between the two treatments (P  0.05 by
Student’s t test). Of 4,416 genes whose expression was correctly
quantified (73% of printed ORFs), 349 genes (8%) showed
statistically significant differences in expression between cryp-
tolepine-treated and untreated cells; of these, 117 genes
showed higher expression in treated cells and 232 appeared to
be downregulated by cryptolepine. Twenty-three of 117 genes
activated upon cryptolepine treatment were included in the
functional class of “response to stress” by GO analysis (Table
2); this was the only functional class detected for upregulated
genes by this analysis. Upregulated genes included five HSP
genes and two genes involved in trehalose synthesis (TSL1 and
TPS1), a typical response of yeast to general stress conditions
(7).
GO analysis of downregulated genes showed several well-
defined functional gene categories (Table 2). This subset of
genes included six of the nine genes involved in siderophore
transport; the expression levels of the remaining three genes
were too low to permit their precise quantification in the ar-
rays. Similarly, the four repressible yeast acid phosphatases
(PHO3, PHO5, PHO11, and PHO12) appeared to be down-
regulated upon cryptolepine treatment. A significant portion
of downregulated genes (8%; P 	 6.7  108) (Table 2)
corresponded to elements of the cell wall, suggesting a specific
action of cryptolepine on this structure. Finally, a small but
significant portion of downregulated genes was related to the
glycolytic and pentose phosphate pathways (Table 2). The pen-
tose phosphate metabolic pathway is known to participate in
the protective response to oxidative stress in yeast (23).
Cryptolepine-induced changes in the expression of genes
belonging to each of the functional categories mentioned
above were corroborated by qRT-PCR (Table 3). The results
from qRT-PCR and microarrays were essentially identical, ex-
cept for an apparent underestimation of the repression levels
for some genes by microarray analysis. There were no signifi-
cant differences between cells treated with 7.5 versus 17 M
cryptolepine (Table 3). Therefore, these combined data indi-
cated decreases in the expression of siderophore transport and
acid phosphatase genes, and enhancement of the expression of
stress-related genes, as a consequence of cryptolepine treat-
ment.
Effects of cryptolepine on Aft1p-regulated genes. The set of
genes regulated by Aft1p, the so-called Aft1p regulon, has
been determined previously by analyzing the transcriptional
differences between Aft1p-deficient (aft1) cells and cells car-
rying the constitutively activated AFT1-1up allele (22). We
compared these results with our data on the effects of crypto-
lepine on erg6 yeast cells. Both data sets showed little or no
correlation for most genes, except for a defined subset that
corresponds to the iron transport-related genes (Fig. 3). The
expression of these genes is strongly dependent on Atf1p (22),
which was downregulated upon cryptolepine treatment. Figure
TABLE 2. GO terms associated with genes significantlya up- or downregulated by cryptolepine
Criterion GO term Clusterfrequencyb
Background
frequencyb P Genes annotated to the term
Downregulated genes
Process Siderophore transport 6/231 (2.6) 9/7,156 (0.1) 3.87 105 FIT1, SIT1, ARN1, ARN2, FIT2, FIT3
Glucose catabolic
process
8/231 (3.5) 26/7,156 (0.4) 4.6 104 CDC19, PGK1, HXK2, ENO2, GND1, PFK2,
RKI1, TKL1
Function Acid phosphatase
activity
4/231 (1.7) 5/7,155 (0.1) 7.4 104 PHO11, PHO3, PHO5, PHO12
Component Fungal-type cell wall 18/231 (7.8) 91/7,156 (1.3) 6.7 108 FLO9, FLO1, ECM33, PHO5, TOS1, DAN3,
EXG2, FIT1, TIR1, CIS3, DAN1, PLB2,
EGT2, GAS5, TIR4, TIR2, FIT2, FIT3
Upregulated genes
Process Response to stress 23/117 (19.7) 487/7,156 (6.8) 7.7 104 SSA1, UGA2, HSP26, UBC4, TPS1, HSP30,
Function No significant ontology
termc
HSP42, SSA4, HSP12, RAD6, ERV1,
CTT1, ZPR1, GRE3, YJL144W, CCP1,
Component No significant ontology
termc
HSP104, TSL1, ALD3, HOR7, NCE103,
YGP1, RFC4
a At a P value of 0.01.
b Expressed as the number of genes/total genes (percentage).
c P  103.
TABLE 3. Cryptolepine-induced changes in the expression of several
genes calculated from microarray and qRT-PCR results
Gene
Log2-transformed gene expression ratioa for cells treated with
cryptolepine at the following concn relative to untreated cells:
7.5 M 17 M
Microarray qRT-PCR Microarray qRT-PCR
ARN2 2.18 4.06 3.32 4.90
FIT3 3.30 5.57 2.36 2.01
PHO5 1.88 1.73 2.05 2.27
TIS11 2.35 3.30 2.31 3.46
HSP26 2.09 2.49 3.54 3.51
TPS1 1.24 0.96 1.01 1.03
a Minus signs indicate downregulation. Data are averages from duplicate ex-
periments for each treatment.
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3 also shows several genes grouped under the “response to
stress” and “fungal-type cell wall” categories, the other two
large functional subsets of genes affected by cryptolepine treat-
ment (see Table 2). For these functional categories, no corre-
lation was observed between the effects of cryptolepine treat-
ment and Aft1p function.
The effects of cryptolepine on genes related to iron transport
are further detailed in Table 4. This table shows all genes that
have been related to iron uptake processes for which we ob-
tained data on the effects of cryptolepine treatment. The genes
were classified by the iron uptake pathway to which they are
related (11) and by their functions (Table 4). Genes of the
siderophore-related pathway were particularly sensitive to
cryptolepine. In addition, the transcription of some genes be-
longing to other iron uptake pathways was also significantly
downregulated. Table 4 also shows that there was a good
correlation between cryptolepine-affected genes and Aft1p-
dependent genes, with some exceptions (notably FRE3 and
FRE6). We conclude that cryptolepine affects genes involved in
iron uptake in yeast, especially those related to the sid-
erophore-dependent pathway and that, in general, the expres-
sion profile coincided with the requirement for Aft1p for the
transcription of these genes.
DISCUSSION
The morbidity and mortality associated with malaria have
encouraged efforts to find novel antimalarial agents with im-
proved potency and selectivity, which include explorations of
cryptolepine and some derivatives (25, 27, 28). In this context,
we have examined changes in the gene expression profile of the
budding yeast S. cerevisiae induced by low doses of cryptol-
epine in order to gain new insights into its mechanisms of
action. By using rather mild conditions, we were able to exam-
ine the effects of this antimalarial drug under conditions under
which its general cytotoxicity was very much reduced. Three
functional subsets of genes changed their expression levels
significantly upon exposure to cryptolepine: general stress
genes, which became activated, and cell wall components and
iron transport genes, which became repressed. These effects
occurred at much lower concentrations than those required for
DNA damage-mediated toxicity and may correlate with the
effects of cryptolepine on plasmodia.
In general, eukaryotic cells respond to DNA damage by
arresting the cell cycle and modulating gene expression to
ensure efficient DNA repair. Various yeast genes involved in
cell cycle arrest after DNA damage are homologous to repair
genes in humans (8). The effects of cryptolepine on repair
genes agree with the higher sensitivity of rad52 yeast strains
to cryptolepine in assays of growth sensitivity to the drug (Fig.
2), indicating that DNA damage is a key factor in the mecha-
nism of cryptolepine cytotoxicity. The results presented here
are relevant to the pursuit of new cryptolepine derivatives with
reduced toxicity; for cryptolepine, toxicity is usually attributed
to its binding to DNA (28). Intriguingly, cryptolepine binds
preferentially to C/G-rich DNA tracts (3, 12); these sequences
are underrepresented in the P. falciparum genome, which con-
tains about 80% AT DNA and therefore a lower number of
potential binding sites than other organisms. Cryptolepine in-
tercalates into DNA (12), and it also inhibits topoisomerase II
(3, 4). However, this inhibition has been suggested to play a
minor role in cytotoxicity (4). Therefore, DNA damage may be
an indirect consequence of treatment with this drug, since
several genes involved in genetic recombination displayed al-
tered patterns of expression after cryptolepine treatment.
The remarkable flexibility of yeast in the use of iron and
other essential nutrients is not completely understood (18),
although iron may be involved in triggering the activation of
some genes. Our results indicate that the expression of a rep-
resentative set of genes involved in iron metabolism, particu-
larly in siderophore-iron complex uptake, is dramatically
changed by cryptolepine (Table 4), a molecule that has been
documented to alter iron usage in other organisms (20). Data
mining revealed that the transcription of iron transport-related
genes was altered by cryptolepine, following a pattern similar
to that observed for Aft1p-deficient cells compared to Aft1-
activated cells. Aft1p is the major regulon responsible for the
remodeling of the yeast transcriptome under conditions of iron
deprivation (22). Lack of Atf1p function results in the inability
of the cell to adapt its metabolism to changes in iron availabil-
FIG. 3. Comparison of changes in transcription rates induced by
cryptolepine treatment (x axis) with those related to Aft1p activity (y
axis). The plot shows two sets of microarray results, both presented as
dual logarithms of relative transcription rates. The y axis includes data
from reference 22 and compares the transcriptome from the aft1
yeast strain to that of an isogenic strain carrying the constitutively
activated AFT1-1up allele. The x axis represents average expression
ratios for cryptolepine-treated versus untreated cells; all treatments
and replicates discussed in the text are included. Genes identified as
implicated in iron uptake, whose names are given in Table 4, are
represented by circles. The correlation between the two data sets for
the iron uptake-related genes (some of which are included in Table 2)
is represented by the corresponding regression line; the correlation
coefficient is also given on the graph. Genes involved in stress, which
correspond to the two major categories affected by cryptolepine as
indicated in Table 2 (cell wall and stress response genes), are also
shown.
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ity and to regulate different cellular processes (22, 24).
Whereas these effects produce only relatively mild growth de-
fects in a facultative respirator such as S. cerevisiae, the changes
observed in the yeast transcriptome may uncover the molecu-
lar origin of cryptolepine’s activity against Plasmodium spp.
Iron assimilation seems to be a common theme in the mech-
anism of several antimalarial drugs. Millimolar concentrations
of chloroquine can prevent iron uptake in yeast (6), resulting in
the upregulation of Aft1p-regulated genes and growth defects
under iron-limiting conditions. The apparently opposite effect
of micromolar concentrations of cryptolepine on the same
regulon should have a synergistic effect, because the combina-
tion of low expression of iron-assimilating genes and preven-
tion of iron assimilation would produce a very severe effect on
the oxidative metabolism of the affected cells. Whether this
cumulative effect occurs in plasmodia remains to be elucidated.
Although experimental evidence supports a high degree of
conservation of the major signaling pathways and basic cellular
processes among simple eukaryotic organisms (16), the occur-
rence of homology and/or orthology among S. cerevisiae and P.
falciparum genes involved in iron usage and metabolism and in
stress response is not, at present, straightforward to establish,
owing to the fact that sequencing of the P. falciparum genome
is ongoing (9). A search among the genes listed in Table 2
failed to produce definitive evidence of orthology between the
iron usage genes in S. cerevisiae and P. falciparum. Neverthe-
less, some of those genes are orthologous in humans; thus,
depletion of iron genes may interfere with labile iron stores in
both host human cells and Plasmodium spp. (18).
Notwithstanding the binding of cryptolepine to DNA, the
main effect of the drug in yeast was clearly on stress re-
sponse. This is at variance with our analysis of the effect of
the DNA-binding antitumor antibiotic daunorubicin using
microarrays, which showed a stronger effect on the control
of gene transcription in the yeast erg6 strain (19). Taken
together, these transcriptomewide studies would indicate
that it is feasible to separate the cytotoxic effect provided by
DNA binding from other pathways that may be ascribed to
the antiplasmodial activity of cryptolepine, such as iron us-
age. This observation may be used in the pursuit of im-
proved molecules related to cryptolepine, which might
hopefully separate those effects (28) even more clearly than
we have described here, through a genomewide analysis of
S. cerevisiae.
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TABLE 4. Aft1p dependence of S. cerevisiae iron transport genes and their inhibition by cryptolepine
Iron uptake pathwaya and function Affinitya,b Gene name Systematicname
Log2-transformed gene expression ratioc for:
Cryptolepine-treated/
untreated cells
aft1/AFT1-1up
cellsd
Siderophore dependent
Facilitator, Fe(III) complex H ARN1 YHL040C 1.07 1.19
H ARN2 YHL047C 3.01 4.64
H SIT1 YEL065W 1.57 3.58
Retention of siderophore-iron
complexes to membrane
H FIT1 YDR534C 2.13 2.72
H FIT2 YOR382W 1.94 4.77
H FIT3 YOR383C 3.46 3.84
Reductase/ferroxidase dependent
Reductases, Fe(III) and Cu(II),
free or complexed
H FRE1 YLR214W 0.78 1.64
H FRE2 YKL220C 0.13 2.26
H FRE5 YOR384W 1.01 1.21
H FRE6 YLL051C 0.08 0.93
Ferroxidases, free Fe(II) H FET3 YMR058W 1.11 3.81
H FET5 YFL041W 0.80 0.63
Reductase/permease dependent
Permeases, ferroxidase-generated
Fe(III)
H FTR1 YER145C 0.49 2.54
H FTH1 YBR207W 0.53 1.39
L FET4 YMR319C 1.79 0.81
Permeases, ferroxidase-generated
Fe(III) and Mn(II)
L SMF1 YOL122C 0.35 0.42
L SMF2 YHR050W 0.09 0.16
L SMF3 YLR034C 1.24 0.40
a Data from reference 11.
b H, high affinity (Km, 2 M); L, low affinity (Km, 
2 M).
c Minus signs indicate downregulation.
d Data from reference 22.
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